With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119139-23-0,3,4-Di(1H-indol-3-yl)-1H-pyrrole-2,5-dione,as a common compound, the synthetic route is as follows.
General procedure: A reaction flask equipped with a magnetic stirrer was charged with a solution of 3, 4-bisindolylmaleimide (2.1 g, 6.4 mmol) in 100 mL of acetone. Potassium hydroxide (0.40 g, 7.1 mmol) was added to the solution at 0 C and stirred for 0.5 h. Iodomethane (1.6 g, 0.011 mol) or 1-bromooctane (2.4 g, 0.012 mol) was added to the reaction mixture for 3, 4-bisindolyl-1-N-methylmaleimide or 3, 4-bisindolyl-1-N-(n-octyl)maleimide, respectively. The reaction mixture was warmed to room temperature and stirred for 1 h (iodomethane) or 24 h (1-bromooctane). The reaction mixture was concentrated and then dissolved in a mixture of ethyl acetate and water. The organic phase was separated, washed with water once and brine once, dried over anhydrous sodium sulfate. The product was purified by flash chromatography with petroleum ether, ethyl acetate and dichloromethane (V/V = 3:1:2) as eluent.
The synthetic route of 119139-23-0 has been constantly updated, and we look forward to future research findings.
Reference£º
Article; Zhang, Qianfeng; Chang, Guanjun; Zhang, Lin; Chinese Chemical Letters; vol. 29; 3; (2018); p. 513 – 516;,
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis